The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients

Essential Tremor Clinical Trial

— AltStim DBS  

Official title:

The Effectiveness of Alternating Ventral Intermediate Nucleus Deep Brain Stimulation Parameters in Preventing Tolerance in Essential Tremor Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02947841
• Other study ID #: 00015871
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: July 2017

Study information

• Verified date: September 2018
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the hypothesis that alternating DBS parameters on a weekly basis will prevent tolerance to stimulation and thus waning of benefit, compared with non-alternating stimulation. The primary endpoint will be preserved tremor control with the alternating group compared with standard treatment using the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS). Key secondary endpoints will be preserved activities of daily living measures as well as preserved tremor control as quantified by motion sensor data.

This study has one primary aim: To determine if alternating DBS stimulation parameters on a weekly basis will be superior at preserving tremor control compared with usual stimulation (non-alternating stimulation) in ET patients with VIM DBS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: July 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with clinically diagnosed ET who have had placement of VIM DBS and are willing to undergo a baseline programming visit and 12-week follow-up assessment

2. At least initial benefit from VIM DBS as judged by patient report and clinician exam

3. VIM DBS placement no less than three months from entry into study

4. Patients must demonstrate ability to use patient programmer to switch between group settings on a weekly basis

5. Ability to wear wrist monitor for 2 week intervals, twice during the study 6. Patients with the following IPG types: Activa PC, SC or RC

Exclusion Criteria:

1. Atypical tremor disorder including but not limited to tremor due to multiple sclerosis, medication-induced tremor, Parkinson's disease or parkinsonian syndrome

2. DBS placement complicated by infection, hemorrhage or stroke

3. Previous thalamotomy (either stereotactic, gamma knife or focused ultrasound) or previous DBS surgery resulting in explantation and reimplantation

4. Known incorrect or poor lead placement

5. Inability to change group settings on a weekly basis at least 75% of the time

6. Inability to tolerate 12-week period without additional programming changes, including voltage stimulation adjustment

7. Inability to tolerate 12-week period without adjustment of anti-tremor medications, including primidone, beta-blockers, gabapentin, topiramate and/or benzodiazepines

8. Battery voltage < or equal to 2.70V

9. Patient with the following IPG types: Soletra, Kinetra or Itrel

10. Inability to tolerate two group settings due to side effects or lack of efficacy

Related Conditions & MeSH terms

• Deep Brain Stimulation
• Essential Tremor
• Tremor

Intervention

Other:
• Alternating stimulation
Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
• Placebo
The control cohort will receive Setting A but Setting B will be identical to Setting A.

Locations

Country	Name	City	State
United States	Oregon Health Science and University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

References & Publications (5)

Baizabal-Carvallo JF, Kagnoff MN, Jimenez-Shahed J, Fekete R, Jankovic J. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014 May;85(5):567-72. doi: 10.1136/jnnp-2013-304943. Epub 2013 Oct 4. — View Citation

Barbe MT, Liebhart L, Runge M, Pauls KA, Wojtecki L, Schnitzler A, Allert N, Fink GR, Sturm V, Maarouf M, Timmermann L. Deep brain stimulation in the nucleus ventralis intermedius in patients with essential tremor: habituation of tremor suppression. J Neurol. 2011 Mar;258(3):434-9. doi: 10.1007/s00415-010-5773-3. Epub 2010 Oct 8. — View Citation

Pilitsis JG, Metman LV, Toleikis JR, Hughes LE, Sani SB, Bakay RA. Factors involved in long-term efficacy of deep brain stimulation of the thalamus for essential tremor. J Neurosurg. 2008 Oct;109(4):640-6. doi: 10.3171/JNS/2008/109/10/0640. — View Citation

Shih LC, LaFaver K, Lim C, Papavassiliou E, Tarsy D. Loss of benefit in VIM thalamic deep brain stimulation (DBS) for essential tremor (ET): how prevalent is it? Parkinsonism Relat Disord. 2013 Jul;19(7):676-9. doi: 10.1016/j.parkreldis.2013.03.006. Epub 2013 Apr 11. — View Citation

Zhang K, Bhatia S, Oh MY, Cohen D, Angle C, Whiting D. Long-term results of thalamic deep brain stimulation for essential tremor. J Neurosurg. 2010 Jun;112(6):1271-6. doi: 10.3171/2009.10.JNS09371. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) performance sub scale at 12 weeks		Through study completion, 12 weeks
Secondary	Change in TETRAS ADLs scale at 12 weeks		Through study completion, at 12 weeks
Secondary	Motion sensor data to detect tremor	Patients will wear motion sensor device to detect tremor characteristics	Two weeks after initial visit; and again at weeks 10-12